Stock Market News1 month Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval Investor's Business Daily
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed.
The post Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval appeared first on Investor's Busi…